Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
39 Cards in this Set
- Front
- Back
|
Lymphoid neoplasm arising as a discrete tissue mass
|
Lymphoma
|
|
|
Myeloid or lymphoid neoplasm that usually presents with involvement of the bone marrow (BM) and/or peripheral blood (PB)
|
Leukemia
|
|
|
Lymphoid cells involving BM and/or PB
|
Lymphocytic leukemia
|
|
|
Myeloid cells involving BM and/or PB
|
Myelogenous Leukemia
|
|
|
Myeloid cells forming discrete tissue mass
|
Myeloid Sarcoma
|
|
|
Plasma cells involving BM and/or PB and/or forming discrete tissue mass
|
Plasma cell myeloma or multiple myeloma
|
|
|
Disease of mature cells of the lymphoid lineage
|
lymphocytic
|
|
|
Disease of immature cells of the lymphoid lineage
|
lymphoblastic
|
|
|
(Leukocyte Common Antigen)...stains all leukocytes
|
CD45
|
|
|
CD16, CD56, cytoplasmic CD3, CD2
|
NK cells
|
|
|
surface CD3, CD2
|
T cells
|
|
|
Always on B cells:
|
CD22
|
|
|
Ig heavy chain (IgH) gene rearrangements
Light chain restriction (κ or λ) (usually kappa) |
B cell neoplasms
|
|
|
T-cell receptor (TCR) gene rearrangements (αβ or γδ)
Down-regulation of surface antigens |
T cell neoplasms
|
|
|
No IgH or TCR gene rearrangements
|
NK cell neoplasms
|
|
|
B lymphoblastic leukemia/lymphoma
|
Bone marrow precursor B cell
Hyperploidy (> 50 chromosomes) t(12;21), t(9;22), t(4;11) TdT CD10 CD19. -------FAVORABLE: Age 4-10 Hyperdiploidy, particularly 51-65 (DNA index of 1.16 and 1.6) with Trisomy 4 Trisomy 10 Trisomy 17 t(12;21) Low or normal leukocyte count at diagnosis ---------UNFAVORABLE: Extremes of age (<1 or >10 years) t(9;22) Translocations involving the MLL gene at 11q23 t(4;11)(q21;q23) t(1;19) Hypodiploidy |
|
|
---seen in blast cells of B and T origin
|
TdT
(terminal deoxynucleotydil transferase) |
|
|
Clinical
Older patients (median age: 60) Hypogammaglobulinemia / autoimmune hemolytic anemia Indolent (often asymptomatic) Immunophenotype CD19 CD20 CD5 CD23 sIg (weak) |
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
|
|
|
Clinical
Middle aged patients Most common NHL in the US (45%) Painless generalized lymphadenopathy Indolent Immunophenotype CD19 CD20 CD10 sIg BCL2 BCL6 Cytogenetics t(14;18) [IgH / BCL2] |
Follicular lymphoma
|
|
|
Clinical
5th to 6th decades Male predominance Indolent, but… moderate survival Immunophenotype CD19 CD20 CD5 sIg Cyclin D1 Cytogenetics t(11;14) [Cyclin D1 / IgH] |
Mantle Cell Lymphoma
|
|
|
Clinical
Middle-aged Caucasian males Splenomegaly, massive Pancytopenia Indolent Immunophenotype CD19 CD20 CD11c CD25 CD103 |
Hairy Cell leukemia
|
|
|
Extra-nodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma / Maltoma)
Associated with chronic inflammatory disorders Infectious (H. pylori in stomach) Autoimmune (Sjogren disease / Hashimoto thyroiditis) Indolent No spread until very late in the course Eradication of inciting agent may cause regression t(11;18) or t(1;14) Splenic MZL Nodal MZL |
Marginal Zone lymphoma
|
|
|
Lymphoplasmacytic lymphoma
Neoplastic plasma cells, lymphocytes, and plasmacytoid lymphocytes throughout the skeletal system, but also in lymph node, spleen, liver. M component (monoclonal IgM) Multiple myeloma (Plasma cell myeloma ) Multiple masses of neoplastic plasma cells throughout the skeletal system M component (monoclonal IgG/A) Plasmacytoma Solitary mass of neoplastic plasma cells in bone or soft tissue M component Monoclonal gammopathy of undetermined significance (MGUS) M components in the blood, with no other signs or symptoms Pre-neoplastic |
Plasma Cell neoplasms
|
|
|
Clinical
6th to 7th decade Monoclonal component (M component) IgM Waldenstrom macroglobulinemia (hyperviscosity sd.) Visual impairment Neurological problems Bleeding Cryoglobulinemia |
Lymphoplasmacytic lymphoma (LPL)
|
|
|
Clinical
50-60 years Multifocal destructive bone tumors Monoclonal component (M component) complete immunoglobulins (IgG or IgA) light chains (Bence-Jones protein) kappa lambda and/or heavy chains Urine Bence Jones proteins (75% of patients) |
multiple myeloma
|
|
|
Clinical
Large age range (median of 60 years) Rapidly enlarging, often symptomatic mass Aggressive but amenable to cure (50%) May be result of progression of less aggressive lymphomas (FL, MZL,CLL, etc.) Immunophenotype CD19 CD20 CD10 (variable) BCL6 (variable) sIg (most) |
Diffuse B cell lymphoma
|
|
|
Immunophenotype
CD19 CD20 CD10 BCL6 sIg Cytogenetics t(8;14) [MYC / IgH] t(2;8) [kappa / MYC] t(8;22) [MYC / lambda] |
Burkitt lymphoma
|
|
|
Clinical
15% of ALL Adolescent males Lymphomas (thymus) Immunophenotype TdT (terminal deoxynucleotydil transferase) CD3 CD7 |
T-lymphoblastic leukemia/lymphoma (T-ALL)
|
|
|
Clinical
Rare Neutropenia Increased incidence of rheumatologic disorders (eg. Felty sd.) Immunophenotype T-cell NK-cell |
Large granular lymphocytic leukemia (LGL)
|
|
|
Clinical
Rare Neutropenia Increased incidence of rheumatologic disorders (eg. Felty sd.) Immunophenotype T-cell NK-cell |
Large granular lymphocytic leukemia (LGL)
|
|
|
Clinical
Human T-cell leukemia virus type 1 (HTLV-1) / Japan Sites Skin lesions Generalized lymphadenopathy Hepatosplenomegaly PB lymphocytosis Hypercalcemia Fatal within 1 year Immunophenotype CD3 CD5 CD4 Negative for CD7 |
Adult T-cell leukemia/lymphoma (ATLL)
|
|
|
Clinical
Children and young adults Soft tissues Good prognosis Immunophenotype CD2 CD4 CD30 ALK (anaplastic large cell lymphoma kinase) Negative for CD3, CD5, CD7 Cytogenetics t(2;5) [NPM;ALK] |
Anaplastic large cell lymphoma (ALCL)
|
|
|
Clinical
Mycosis fungoides Skin patches and plaques Sézary syndrome Erythroderma Generalized lymphadenopathy Circulating Sézary cells in PB Immunophenotype CD3 CD5 CD4 Negative for CD7 |
Mycosis fungoides/Sézary syndrome (MF/SS)
|
|
|
Clinical
Lethal midline granuloma Rare in US 3% of NHL in Asia Destructive midline mass involving the nasopharynx Immunophenotype cCD3 CD56 |
Extranodal NK/T-cell lymphoma
|
|
|
Clinical
5% of HL Young males Lymphadenopathy Cervical Axillary mediastinal Immunophenotype CD20 CD45 Negative for CD30, CD15 |
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
|
|
|
Clinical
70% of HL Young adults Mediastinum Immunophenotype CD30 CD15 Negative for CD45, CD20 |
Nodular sclerosis Hodgkin lymphoma (NSHL)
|
|
|
Clinical
20% of HL Biphasic peak incidence (young adults and >55years) Immunophenotype CD15 CD30 Negative for CD45, CD20 EBV (70%) |
Mixed cellularity Hodgkin lymphoma (MCHL)
|
|
|
Clinical
5% of HL Immunophenotype CD15 CD30 Negative for CD45, CD20 EBV (40%) |
Lymphocyte rich classical Hodgkin lymphoma (LRCHL)
|
|
|
Clinical
Very rare Associated with HIV Immunophenotype CD15 CD30 Negative for CD45, CD20 EBV (most) |
Lymphocyte-depleted Hodgkin lymphoma (LDHL)
|
